ABM

Tango Therapeutics, Inc.

Fundamental data last updated:July 9, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

 


Analyze ABM on TradingView

VALUATION

P/E

-26.78

Market Cap ($M USD)

$2.32B

Forward P/E

25.09

PEG

0.12

PRICE TO SALES

40.77

PRICE TO BOOK

7.33

EV / EBITDA

-19.41

5-Year Average P/E

Free Cash Flow Yield

-6.14%

DCF Value

$-13.77

Graham Number

N/A

Price to FCF

-16.30

EV to FCF

-15.42

Earnings Yield

-3.73%

FCF Yield

-6.14%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.75

Next Year EPS Growth Estimate

$0.80

Next Year Revenue Growth Estimate

$63.78B

Return on Equity (ROE)

-41.54%

FREE CASH FLOW

Operating Margin

-206.22%

Debt-to-Equity

0.10

Piotroski F-Score

2

Altman Z-Score

29.28

Return on Invested Capital (ROIC)

-27.89%

Current Ratio

27.38

Quick Ratio

27.38

Net Debt to EBITDA

1.10

Interest Coverage

0.00

Gross Profit margin

97.25%

FCF PER SHARE

$-0.99

REVENUE PER SHARE

$0.40

Analyze ABM on TradingView

Gainseekers Quantitative Analysis

Summary

Tango Therapeutics, Inc. is a perplexing case of valuation extremes. Despite a staggering negative DCF value, the market has priced it with a Forward P/E of 30.63, suggesting optimism about future earnings. The Altman Z-score of 28.71 indicates financial stability, yet the negative earnings yield and ROIC of -29.52% highlight inefficiencies. The stock’s current valuation appears misaligned with its intrinsic value, raising questions about its long-term growth prospects. Investors should be wary of the disconnect between market enthusiasm and fundamental weaknesses.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Tango Therapeutics is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology provides a fertile ground for innovation. However, the rapid pace of tech evolution demands agility and continuous adaptation.

The Bull Case

For the value-driven investor, Tango Therapeutics offers a compelling narrative. Despite a low Piotroski F-Score of 2, the company's minimal debt and robust current ratio of 16.32 suggest strong liquidity and financial resilience. The gross profit margin of 97.34% indicates significant pricing power, while the forward PEG ratio of 0.16 suggests potential undervaluation relative to growth. These factors could appeal to those seeking a high-risk, high-reward opportunity.

The Bear Case

The stock's vulnerabilities are glaring. With a Price/Sales ratio of 42.87 and Price/Book of 7.72, it is trading at lofty multiples, raising red flags about overvaluation. The negative FCF yield and operating margin of -178.39% underscore severe cash flow challenges. Additionally, its proximity to the 52-week high suggests technical overextension, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$34.83

Institutional Ownership %

1-Year Beta

1.22

Insider Buying % (6 Mo)

Distance to 52-Week High

42.05%

Distance to 52-Week Low

89.40%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$22.19

200-DAY SMA

$12.82

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.